Bandaríkin - enska - NLM (National Library of Medicine)

rebel distributors corp - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablet and other antibacterial drugs, clarithromycin tablet should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin tablet is indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective

Bandaríkin - enska - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablet and other antibacterial drugs, clarithromycin tablet should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin tablet is indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective

Bandaríkin - enska - NLM (National Library of Medicine)

wockhardt limited - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablet and other antibacterial drugs, clarithromycin tablet should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin tablet is indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective

Bandaríkin - enska - NLM (National Library of Medicine)

dispensing solutions, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets, usp and other antibacterial drugs, clarithromycin extended-release tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin extended-release tablets, usp are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below: acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis , or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, haemophilus parainflu

Austurríki - þýska - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ratiopharm arzneimittel vertriebs-gmbh - clarithromycin -

Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

abz-pharma gmbh - geschäftsanschrift - (4238075) - clarithromycin - filmtablette - teil 1 - filmtablette; clarithromycin (23929) 500 milligramm

Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

abz-pharma gmbh - geschäftsanschrift - (4238075) - clarithromycin - filmtablette - teil 1 - filmtablette; clarithromycin (23929) 250 milligramm

Grikkland - gríska - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - clarithromycin - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 500mg/tab - clarithromycin 500mg - clarithromycin

Grikkland - gríska - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - clarithromycin - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 250mg/tab - clarithromycin 250mg - clarithromycin

Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - clarithromycine 25 mg/ml - granulaat voor orale suspensie - 125 mg/5 ml - clarithromycine 25 mg/ml - clarithromycin